Stay updated on PD-1 Inhibition & Ablation for Advanced HCC Clinical Trial
Sign up to get notified when there's something new on the PD-1 Inhibition & Ablation for Advanced HCC Clinical Trial page.

Latest updates to the PD-1 Inhibition & Ablation for Advanced HCC Clinical Trial page
- Check4 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check47 days agoChange DetectedThe webpage has been updated to include a new study on the combination of anti-PD-1 therapy and incomplete thermal ablation for advanced hepatocellular carcinoma (HCC), with a focus on specific patient eligibility criteria and the principal investigator's name. The previous version's detailed background information on PD-1 inhibitors and their efficacy in HCC treatment has been removed.SummaryDifference28%
- Check54 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check90 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check111 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
Stay in the know with updates to PD-1 Inhibition & Ablation for Advanced HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PD-1 Inhibition & Ablation for Advanced HCC Clinical Trial page.